List of Excipients in Branded Drug FOLIC ACID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Apace Packaging	FOLIC ACID	folic acid	15338-170	CELLULOSE, MICROCRYSTALLINE
Apace Packaging	FOLIC ACID	folic acid	15338-170	LACTOSE MONOHYDRATE
Apace Packaging	FOLIC ACID	folic acid	15338-170	SODIUM STARCH GLYCOLATE TYPE A POTATO
Apace Packaging	FOLIC ACID	folic acid	15338-170	STEARIC ACID
Ayurax LLC	FOLIC ACID	folic acid	73308-501	EDETATE DISODIUM

Generic Drugs Containing FOLIC ACID

Company	Ingredient	NDC	Excipient
Par Pharmaceutical	folic acid	0603-3162	CELLULOSE, MICROCRYSTALLINE
Par Pharmaceutical	folic acid	0603-3162	LACTOSE MONOHYDRATE
Par Pharmaceutical	folic acid	0603-3162	SODIUM STARCH GLYCOLATE TYPE A POTATO
Par Pharmaceutical	folic acid	0603-3162	STEARIC ACID
NCS HealthCare of KY LLC dba Vangard Labs	folic acid	0615-7814	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in FOLIC ACID?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	BENZYL ALCOHOL
90	CELLULOSE, MICROCRYSTALLINE
2	EDETATE SODIUM
1	HYDROCHLORIC ACID

Folic Acid Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Folic acid is a low-cost, mature vitamin drug with limited active-ingredient patent protection and broad generic availability. Commercial differentiation depends on formulation performance, dose flexibility, stability, patient adherence, pediatric suitability, and regulatory positioning rather than on new chemical entity exclusivity. The strongest opportunities are low-dose oral liquids, orally disintegrating tablets, prenatal combination products, pharmacy-compounded formulations, and stable products that combine folic acid with iron, vitamin B12, iodine, or other micronutrients.

What is the regulatory and commercial status of folic acid?

Folic acid, also known as pteroylglutamic acid or vitamin B9, is marketed as an active pharmaceutical ingredient in prescription tablets, oral supplements, fortified foods, and injectable products. In the United States, common pharmaceutical strengths include 0.4 mg, 0.8 mg, 1 mg, and 5 mg, although product availability varies by manufacturer and channel.

The principal regulatory characteristics are:

Attribute	Folic acid
Active ingredient	Folic acid, pteroylglutamic acid
Therapeutic category	Vitamin replacement; megaloblastic anemia prevention and treatment
Common oral strengths	0.4 mg, 0.8 mg, 1 mg, 5 mg
Common dosage forms	Tablets, capsules, oral liquids, gummies, injectable products
Prescription status	Prescription and nonprescription products, depending on strength and labeling
FDA pathway	Abbreviated New Drug Application for generics; OTC and dietary supplement pathways also apply
Patent position	Core active ingredient and conventional products are long off-patent
Main differentiation	Delivery system, combination product, stability, taste, dose flexibility, and packaging

Folic acid is distinct from folinic acid, also called leucovorin, and from 5-methyltetrahydrofolate. These compounds should not be treated as interchangeable for labeling, bioequivalence, or intellectual-property analysis.

The FDA’s Orange Book is relevant for approved prescription folic acid products, but the commercial market is dominated by generic and nonprescription products rather than an originator franchise. Orange Book listings should be reviewed product by product because listing status, active ingredients, strengths, and dosage forms can differ among sponsors. The FDA Inactive Ingredient Database is also relevant when selecting excipients for new strengths or dosage forms.[1,2]

What excipient properties matter most for folic acid formulations?

The principal formulation problem is that folic acid has limited aqueous solubility and can degrade under unfavorable light, pH, oxygen, and heat conditions. A successful excipient strategy must control dispersion, content uniformity, taste, moisture exposure, and photostability.

Solubility and pH control

Folic acid is poorly soluble in water under acidic and neutral conditions. Solubility increases in alkaline environments, but excessive alkalinity can create stability and tolerability problems. Direct pH adjustment is therefore more useful in liquid systems than in conventional immediate-release tablets.

For oral liquids, formulators may use:

• Sodium citrate or citrate buffers
• Phosphate buffers where compatible with the full formula
• Sodium hydroxide or other pH adjusters
• Glycerin, propylene glycol, or polyethylene glycol as co-solvents
• Polysorbates or other wetting agents when justified
• Suspending agents such as xanthan gum, sodium carboxymethylcellulose, or hydroxypropyl cellulose

A clear solution is commercially attractive but may require alkaline pH, higher excipient load, and tighter packaging controls. A suspension can offer better chemical stability and broader pH flexibility, but it requires shake instructions, sedimentation control, and robust dose uniformity.

Light protection

Folic acid is light-sensitive. Amber bottles, opaque unit-dose packaging, aluminum foil blisters, and secondary cartons can reduce photodegradation. The packaging decision should be made with the excipient system, not after formulation development.

Light-protection claims should be supported by photostability studies under ICH Q1B conditions. A clear bottle may be acceptable for a short-use product only if the formulation and packaging data demonstrate adequate protection.[3]

Moisture control

Moisture can impair tablet physical properties and accelerate degradation in hygroscopic excipient systems. The most practical controls are:

• Low-moisture direct-compression excipients
• Moisture-barrier film coatings
• High-barrier blister packs
• Desiccants for multidose bottles
• Low-water-activity liquid or semisolid systems
• Controlled manufacturing humidity

Mannitol is often attractive for orally disintegrating products because it provides a dry mouthfeel and relatively low hygroscopicity. Microcrystalline cellulose, anhydrous dibasic calcium phosphate, and selected spray-dried excipients can support direct compression, but compatibility and dissolution must be confirmed.

Content uniformity

Folic acid is usually present at a low dose relative to the tablet mass. Blend segregation and poor API dispersion can create content-uniformity failures. A premix or ordered mixing process may be preferable to simple geometric dilution, particularly for 400 microgram and 800 microgram products.

Potential approaches include:

• API pre-dispersion onto a carrier
• Spray-dried folic acid premixes
• Wet granulation where stability permits
• Low-shear blending followed by validated lubrication
• In-process near-infrared monitoring
• Unit-dose powder filling for customized products

The critical quality attribute is not only assay. Uniformity of dosage units, dissolution, degradation products, and stability through shelf life require separate control.

What formulations are protected by excipient and delivery strategy?

Conventional folic acid tablets have limited differentiation. More defensible commercial positions involve delivery systems that solve a specific patient or manufacturing problem.

Immediate-release tablets

Immediate-release tablets are the lowest-risk and lowest-margin format. Typical excipient systems include:

• Microcrystalline cellulose or lactose as fillers
• Povidone or pregelatinized starch as binders
• Croscarmellose sodium or sodium starch glycolate as disintegrants
• Magnesium stearate or sodium stearyl fumarate as lubricants
• Film coatings based on hypromellose, polyethylene glycol, titanium dioxide, and colorants

The main commercial advantage is low manufacturing cost. The principal risks are price competition, limited product differentiation, and low barriers to substitution.

Orally disintegrating tablets

ODTs can improve adherence in patients with dysphagia, pregnant patients experiencing nausea, and pediatric users. Mannitol-based ODTs are suitable for sweet, rapidly disintegrating products. Crospovidone, croscarmellose sodium, or low-substituted hydroxypropyl cellulose can support rapid breakup.

Key development targets include:

• Disintegration within the applicable compendial or product-specific limit
• Low friability
• Adequate mechanical strength
• Pleasant taste and low aftertaste
• Protection from humidity
• Unit-dose packaging

Taste masking is difficult because folic acid may have a distinctive bitter or medicinal taste. Flavors, sweeteners, ion-exchange resins, lipid barriers, and polymeric coating systems can be assessed. A taste-masked ODT can command a premium over a standard tablet if the label supports pediatric or adherence-related use.

Oral solutions and suspensions

Liquid folic acid products address pediatric dosing, feeding-tube administration, geriatric use, and pharmacy-compounded demand. The main technical choice is between a true solution and a suspension.

A solution requires sufficient solubilization and chemical stability. A suspension requires particle-size control, sedimentation management, redispersibility, and dose uniformity after storage. Xanthan gum, cellulose derivatives, glycerin, and sorbitol are common development candidates, but each can affect viscosity, microbial preservation, and pourability.

Preservatives may be necessary in multidose aqueous products. Options must be evaluated against age restrictions, hypersensitivity concerns, preservative efficacy, and the total formulation pH. Single-dose sachets or unit-dose cups can eliminate some preservative and in-use stability issues.

Gummies and chewable products

Gummies and chewables are commercially attractive in prenatal and consumer health channels. They create challenges for folic acid because of:

• Low-dose uniformity across a viscous matrix
• Heat exposure during manufacturing
• Water activity and microbial control
• Flavor masking
• Color stability
• Migration or crystallization during storage

Gummies are more naturally positioned as dietary supplements than prescription drugs. A sponsor seeking drug approval must maintain appropriate control of dosage, manufacturing, labeling, and stability. The commercial opportunity is strongest where the product combines folic acid with iron, iodine, vitamin D, vitamin B12, or omega-3 components.

Injectable products

Injectable folic acid products require a different excipient strategy. The formulation must address solubility, pH, particulate control, sterility, endotoxin, container closure, and compatibility with the administration system.

Potential components include:

• Water for Injection
• pH adjusters
• Buffer systems where justified
• Sodium folate or another soluble folate form where the approved active ingredient and clinical rationale permit

The use of a soluble folate salt changes the chemistry and regulatory basis of the product. It is not a simple excipient substitution. Injectable products face higher development and manufacturing costs but may have less direct competition than basic tablets.

How should formulators manage folic acid compatibility?

Folic acid should be evaluated against the complete excipient matrix rather than tested only as a binary API-excipient mixture.

Risk area	Potential issue	Development response
Reducing sugars	Maillard-type interactions may be relevant in certain systems	Conduct binary and full-formula compatibility studies
Metal ions	Oxidative or catalytic degradation risk	Assess chelators and raw-material specifications
Light	Photodegradation	Use opaque or amber packaging and conduct photostability studies
Alkaline pH	Improved solubility but possible degradation or tolerability concerns	Define pH operating range experimentally
Moisture	Degradation, sticking, altered hardness	Use low-moisture excipients and barrier packaging
Lubricants	Slower wetting or dissolution at high levels	Optimize concentration and blending time
Preservatives	Chemical or sensory incompatibility	Validate preservative efficacy and assay recovery
Iron and minerals	Color, oxidation, dissolution, and stability interactions	Separate microenvironments or use protective coating and chelation strategy

Iron-folic acid combinations are commercially important but technically difficult. Iron salts can darken formulations, alter dissolution, and increase degradation risk. Ferrous fumarate, ferrous sulfate, and iron polymaltose systems should be screened separately. Coated iron particles, dry-layer tablets, bilayer tablets, or multiparticulate systems can reduce direct contact between iron and folic acid.

Vitamin B12 combinations require attention to light and oxidation. Iodine-containing prenatal products raise additional questions about dose uniformity, volatility, and compatibility with the package.

When does folic acid lose exclusivity?

Folic acid’s basic molecule, conventional tablet formulations, and standard therapeutic uses are long off-patent. Generic entry risk is therefore high for conventional oral products. The relevant competitive barrier is usually regulatory execution and manufacturing economics rather than patent exclusivity.

A sponsor may still obtain protection for:

• A novel dosage form
• A specific excipient ratio
• A taste-masking system
• A controlled-release formulation
• A stabilized liquid composition
• A combination product
• A manufacturing process
• A specialized package or unit-dose system

Such claims must provide a technical distinction that is not predictable from the known use of folic acid. Broad claims covering “folic acid plus conventional excipients” are likely to face validity and obviousness pressure.

What is the Orange Book and Paragraph IV risk for folic acid?

Orange Book and Paragraph IV exposure is generally concentrated in any newly approved branded product that claims a specific formulation, delivery system, or combination. A generic applicant for a conventional folic acid tablet would usually face little practical patent risk because the fundamental product is mature and widely marketed.

For a differentiated product, the risk analysis should include:

1. Orange Book-listed patents for the reference product.
2. Patent expiration and pediatric-extension dates.
3. Formulation and method-of-use claims.
4. Paragraph IV certifications filed by generic applicants.
5. ANDA litigation under the Hatch-Waxman Act.
6. Non-Orange Book patents covering manufacturing, packaging, or device components.
7. State-law and trade-secret protection for manufacturing methods.

Patent litigation is more likely to arise around a premium delivery system or combination product than around standard folic acid tablets. Settlement agreements, if reached, may include licensed entry dates, authorized generic provisions, or restrictions on particular dosage forms. These terms must be reviewed in the relevant court docket and FDA regulatory records rather than inferred from the presence of a patent listing.

What commercial opportunities exist for folic acid products?

The most credible opportunities are formulation-led.

Pediatric and dysphagia products

A low-volume oral suspension, unit-dose sachet, or rapidly disintegrating tablet can address pediatric dosing and administration through feeding tubes. The strongest value proposition is dose flexibility supported by validated oral-device accuracy.

Prenatal combination products

Prenatal products have established demand, but competition is intense. Differentiation can come from:

• Reduced tablet size
• Lower gastrointestinal burden
• Separate iron and vitamin layers
• Better taste
• Low-nausea formulations
• Folate plus B12 and iodine combinations
• Unit-dose blister packaging
• Products designed for early pregnancy and preconception use

Pharmacy and institutional products

Hospitals, fertility clinics, long-term-care facilities, and compounding pharmacies may value preservative-free liquids, unit-dose presentations, and reliable high-strength products. These channels favor packaging accuracy and supply continuity over consumer branding.

Global and public-health supply

Folic acid is used in maternal-health programs and food-fortification initiatives. Commercial opportunities include stable, low-cost tablets, premixes for fortified foods, and products adapted to hot, humid climates. Aluminum-based blister packaging and high-barrier bottles may justify a modest cost increase where distribution conditions are severe.

Manufacturing and licensing

Licensing opportunities are more likely to involve a formulation platform than folic acid itself. Potential deal structures include:

• Regional rights to a pediatric liquid
• Contract manufacturing of prenatal combinations
• Co-development of ODT technology
• Supply agreements for stabilized folic acid premixes
• Technology transfer for high-barrier packaging
• Private-label manufacturing for retail and institutional buyers

Revenue exposure for a conventional tablet is usually limited by low unit price and multiple generic competitors. A differentiated liquid, ODT, or combination product can produce higher gross margin but requires stronger evidence for stability, taste, packaging, and patient benefit.

How strong is the patent estate for folic acid products?

The patent estate is weak for the base drug and stronger only where the product includes a defensible formulation or delivery innovation.

Product type	Patent strength	Generic substitution risk	Commercial outlook
Standard 1 mg tablet	Low	Very high	Commodity
5 mg tablet	Low	Very high	Institutional and prescription demand
Oral solution	Moderate if technically differentiated	Moderate	Pediatric and specialty opportunity
ODT	Moderate	Moderate	Premium adherence product
Prenatal combination	Moderate	Moderate to high	Strong consumer and clinical competition
Stabilized injectable	Moderate to high if novel	Lower	Smaller, specialized market
Novel controlled-release system	Potentially high	Lower initially	Requires substantial development evidence

Geographic protection will usually be fragmented. U.S. freedom-to-operate analysis should be separated from European, Japanese, Chinese, and emerging-market reviews because patent term, regulatory exclusivity, food-versus-drug classification, and enforcement standards differ.

What is the recommended excipient strategy?

For a commercial folic acid program, the most practical sequence is:

1. Establish the target dosage form and patient group.
2. Select a low-moisture, low-segregation powder platform for tablets.
3. Screen pH, light, oxygen, metal-ion, and moisture effects.
4. Develop the packaging concurrently with the formulation.
5. Use a premix or granulation strategy for microgram-dose products.
6. Separate folic acid from iron and other reactive minerals when developing combinations.
7. Validate dose uniformity, dissolution, assay, impurities, microbial quality, and in-use stability.
8. Pursue patent claims around a measurable formulation advantage rather than routine excipient selection.
9. Align the product with the correct FDA pathway: ANDA, NDA, OTC, or dietary supplement.
10. Position the commercial product around adherence, pediatric administration, stability, or combination convenience.

Key Takeaways

• Folic acid is a mature, low-cost active ingredient with minimal core patent protection.
• Conventional tablets face high generic and price competition.
• Excipient selection should focus on solubility, light stability, moisture control, low-dose uniformity, taste, and mineral compatibility.
• Oral liquids, ODTs, unit-dose products, and prenatal combinations offer the clearest commercial differentiation.
• Iron-folic acid products require deliberate separation or stabilization strategies.
• Novel excipient combinations alone may not support strong patent protection unless they produce a demonstrated technical effect.
• Packaging is a central part of the folic acid stability strategy.
• The best licensing opportunities involve formulation platforms, pediatric delivery, prenatal combinations, and regional manufacturing rights.

FAQs

Can folic acid be formulated as a clear oral solution?

Yes, but the formulation may require alkaline pH adjustment, co-solvents, buffering, and light-protective packaging. A suspension may provide better stability and simpler manufacturing.

Is sodium folate a better commercial ingredient than folic acid?

Sodium folate may improve aqueous solubility, particularly in liquid or injectable systems. It creates a separate regulatory and formulation basis and should not be treated as a routine excipient change.

Which packaging is best for folic acid tablets?

High-barrier blister packaging or opaque, moisture-resistant bottles with desiccant protection are generally stronger options than unprotected clear multidose packaging. The final selection must follow photostability and accelerated-stability data.

Can folic acid be combined with iron in a single tablet?

Yes. The combination is widely used, but iron can affect color, dissolution, oxidation, and folic acid stability. Bilayer tablets, coated iron particles, separate granules, or controlled microenvironments can reduce compatibility problems.

Does an ODT folic acid product have meaningful patent potential?

Potentially. Stronger patent positions may arise from a defined taste-masking system, rapid-disintegration platform, moisture-protective architecture, or specific stability improvement. Routine use of mannitol and a conventional superdisintegrant is less likely to provide durable protection.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. International Council for Harmonisation. (1996). ICH Q1B: Photostability testing of new drug substances and products. https://www.ich.org

4. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. National Institutes of Health, Office of Dietary Supplements. (2024). Folate fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/